Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8TE12
UPID:
LMX1A_HUMAN
Alternative names:
LIM/homeobox protein 1.1; LIM/homeobox protein LMX1A
Alternative UPACC:
Q8TE12; B3KXP6; Q0VDB5; Q5VWG4; Q8TE11
Background:
LIM homeobox transcription factor 1-alpha, also known as LMX1A, plays a pivotal role in the development of the central nervous system and vertebrae. It functions as a transcriptional activator, crucial for the development of the roof plate and specification of dorsal cell fates. Its activity involves binding to the FLAT element in the insulin gene promoter, highlighting its significance in gene expression regulation.
Therapeutic significance:
LMX1A is linked to Deafness, autosomal dominant, 7 (DFNA7), a form of non-syndromic sensorineural hearing loss. This condition underscores the protein's clinical relevance, as it presents a target for therapeutic intervention. Understanding the role of LIM homeobox transcription factor 1-alpha could open doors to potential therapeutic strategies for sensorineural deafness.